[Estimation of soluble serum CD30 in the diagnosis of early renal allograft dysfunction].
We aimed to reveal factors influencing serum soluble CD30 level in the recipients of kidney allograft and to estimate its pathogenetic significance. We tested the sCD30 level in the serum before and the 4th day after operation by ELISA. It was established, thats CD30 levels before transplantation were virtually the same in patients who experienced rejection and in non-rejecting patients. However, there was a significant decrease in the level of sCD30 after transplantation in non-rejecting patients, contrary to rejecting patients. A significant decrease of sCD30 level was detected on the day 4th after the transplantation independently of dialysis requirement. The decrease of sCD30 on the day 4th after operation in the patients with delayed graft function and its stability in the patients with acute rejection may be used distinguish these complications.
Trailin
A V
AV
D015415:Biomarkers / Q000097:blood; D042241:Early Diagnosis; D004797:Enzyme-Linked Immunosorbent Assay; D006084:Graft Rejection / Q000097:blood* / Q000276:immunology; D006801:Humans; D017730:Ki-1 Antigen / Q000097:blood*; D016030:Kidney Transplantation; D015166:Monitoring, Immunologic; D011237:Predictive Value of Tests; D012995:Solubility; D014019:Tissue Donors
D015415:Biomarkers; D017730:Ki-1 Antigen